CytoNiche Receives Top Bioprocessing Honour at ABEA 2026

Date : 2026-03-12

Publisher : Cytoniche | Marketing

Cytoniche Honoured with "Emerging Bioprocessing Supplier Award: Downstream Processing" at ABEA 2026

SINGAPORE — CytoNiche is proud to announce that it has been named the winner of the Emerging Bioprocessing Supplier Award: Downstream Processing at the Asia Pacific Biopharma Excellence Awards (ABEA) 2026.

The award ceremony, held at the Sands Expo & Convention Centre in Singapore on Wednesday, 11th March, brought together the most innovative leaders and organisations in the Asia-Pacific biopharmaceutical sector. The Asia-Pacific Biopharma Excellence Awards (ABEA) 2026 honours outstanding achievements in Asian bioprocessing, logistics, supply chain management, and clinical trials, celebrating current industry leaders while inspiring future innovators across the region.

This prestigious recognition highlights CytoNiche's outstanding contributions to advancing biopharma excellence in the region, particularly in the field of 3D cell manufacturing and regenerative medicine. This accolade recognises Cytoniche’s outstanding contributions to advancing biopharma excellence through cutting-edge solutions that optimise downstream workflows and enhance production efficiency.

Recognising Excellence in Downstream Innovation

Dr. Yan Xiaojun, Co-founder & CTO of CytoNiche Bioetch said:
This award is more than a trophy; it is a validation of our vision to industrialise cell manufacturing. At the heart of this success is our 3D TableTrix™ Microcarrier—a porous, biodegradable scaffold specifically engineered to harmonise high-yield cell expansion with seamless downstream harvesting. Being recognised by our peers in the Asia-Pacific region motivates us to continue pushing the boundaries of what is possible in bioprocessing—ensuring these life-saving treatments are both scalable and accessible.

Scaling the Future of Biopharma

As "Cell Architects", CytoNiche has pioneered the transition from antiquated 2D manual cultures to scalable, high-fidelity 3D microcarrier suspension systems. The TableTrix™ Microcarrier serves as the cornerstone of this evolution, offering a biomimetic environment that maximises cell viability and potency. Its bespoke, dissolvable properties are specifically engineered to eliminate the traditional bottlenecks of cell-carrier separation, facilitating a seamless transition to downstream processing.

By integrating these sophisticated downstream capabilities with automated 3D cell manufacturing instrumentation, CytoNiche delivers a truly end-to-end solution for cell and gene therapy (CGT) manufacturers. This holistic approach empowers partners to transcend laboratory-scale research and achieve robust industrial-scale production. By harmonising "Quality and Quantity", CytoNiche effectively streamlines the manufacturing continuum, significantly accelerating the path to clinical application and global patient access.

Looking Ahead

The ABEA 2026 glass trophy and certificate of excellence serve as a symbol of Cytoniche’s trajectory as a global leader in bioprocessing. As the company continues to expand its footprint across Asia and beyond, it remains focused on its core mission: advancing global access to cell technologies through disruptive and scalable manufacturing innovations.

CytoNiche Successfully Conducts High DecaGiga Cell Manufacturing Masterclass

The Industrial Engine for NK Cell Therapy: Scaling NK Cell Therapy with 3D FloTrix™ NK Serum-Free Medium Kit (RNK59)